Boston Scientific shares rise on strong Q1 results, raised EPS guidance

Published 23/04/2025, 12:02
© Reuters.

Investing.com -- Boston Scientific Corporation reported first-quarter earnings and revenue that surpassed analyst expectations, driving shares up 3.2% in early trading Wednesday.

The medical device maker posted adjusted earnings per share of $0.75 for Q1 2025, beating the consensus estimate of $0.67. Revenue came in at $4.66 billion, topping expectations of $4.57 billion and representing a 20.9% increase YoY.

Boston Scientific (NYSE:BSX) saw robust growth across its business segments. Cardiovascular sales jumped 26.2% YoY to $3.09 billion, while MedSurg revenue rose 11.7% to $1.58 billion.

"We delivered an exceptional quarter to start the year, reflecting the effectiveness of our highly engaged global team and the strength of our product portfolio," said Mike Mahoney, chairman and CEO of Boston Scientific.

The company raised its full-year 2025 adjusted EPS guidance to a range of $2.87 to $2.94 from $2.80-$2.87, also above the analyst consensus of $2.86. It expects organic revenue growth of 12% to 14% for the year.

For Q2 2025, Boston Scientific projects organic revenue growth of 13% to 15% and adjusted EPS between $0.71 and $0.73.

"We delivered an exceptional quarter to start the year, reflecting the effectiveness of our highly engaged global team and the strength of our product portfolio," said Mike Mahoney, chairman and chief executive officer of Boston Scientific. "We remain well-positioned for the future as we continue to focus on meaningful innovation, clinical science and the execution of our category leadership strategy to drive differentiated growth and performance for the long-term."

 

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.